Background {#Sec1}
==========

The management of many chronic diseases depends chiefly on the assumption that the medications prescribed by the clinician are taken by the individual being treated. Medication adherence is defined as the extent to which prescribed medications are taken according to the dosage and frequency recommended by the provider \[[@CR1]\]. It is estimated, however, that between 30 and 50% of people do not take their medications as prescribed \[[@CR2]\]. Theories as to the causes of non-adherence generally recognise socio-economic, healthcare system, condition- and patient-related factors \[[@CR3]\]. Methods to combat non-adherence are wide-ranging; from practical interventions, to behaviour change interventions targeting psychological barriers to medication use \[[@CR4]\]. The resulting costs of non-adherence are both human, the individual not gaining the benefit of treatment, and economic \[[@CR5]--[@CR7]\], resulting in unused medication, for example. Older people are particularly susceptible to non-adherence due to multi-morbidity associated polypharmacy \[[@CR8]\], and owing to particular constraints such as physical, cognitive or sensory impairments \[[@CR9]\].

In this review polypharmacy is the taking of any medication that is potentially inappropriate, rather than exceeding a defined number of drugs \[[@CR10]\] because adherence to an inappropriate medication can lead to harm. However, available evidence regarding polypharmacy and drug adherence in the older population living at home is scarce \[[@CR11]\]. Most studies have focused on improving adherence to one drug group, and thus have limited applicability to the older population who commonly use multiple medications \[[@CR12]--[@CR14]\].

The term 'deprescribing' is the process of the gradual withdrawal and cessation of potentially inappropriate medications, supervised by a healthcare professional with the goal of reducing unnecessary medications and their related problems \[[@CR15]\]. Deprescribing attempts to balance the potential for benefit and harm by systematically withdrawing inappropriate medications with the goal of managing polypharmacy and improving outcomes \[[@CR16]\]. Guidelines that have been developed to facilitate this process advocate involving the individual themselves in decisions relating to their prescription \[[@CR17]--[@CR20]\]. In spite of their potential to improve safety, significant barriers to these interventions exist \[[@CR21]--[@CR23]\].

Previous studies have examined the impact of deprescribing processes in residential care settings \[[@CR24]\]. To the best of the authors' knowledge, there has been no investigation as to the potential of deprescribing as an effective strategy for improving medication adherence in community-dwelling older adults. This is a population who are largely independent and live in their own home, but for whom the number, dosage and complexity of medications demands considerable health literacy \[[@CR25], [@CR26]\].

The aim of the review was to explore the impact of deprescribing interventions on adherence measures in this unique population.

Methods {#Sec2}
=======

A mixed methods systematic review of the literature was undertaken on deprescribing interventions and medication adherence in community-dwelling older adults with polypharmacy. Registered as PROSPERO CRD42017075315, this systematic review used qualitative and quantitative data to explore a range of factors associated with the effectiveness of deprescribing interventions in tackling medication non-adherence, and in doing so, offers a more complete picture of the area of investigation \[[@CR27]\]. The search, screening, quality appraisal and data extraction processes were led by an Information Scientist (DH) and the lead for the review team (JU). This systematic review is reported in accordance with the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) statement.

Eligibility criteria {#Sec3}
--------------------

Papers were selected using the criteria as follows. Study type: primary qualitative, quantitative or mixed methods studies were sought. Protocols, conference abstracts, academic thesis, editorials, commentaries and opinion articles were excluded. Review papers were excluded, but were used to cross-check for relevant primary papers. Population: papers must have reported data on community dwelling older people (aged ≥65 years) experiencing polypharmacy. In this review, polypharmacy is the taking of any medication that is potentially inappropriate, rather than exceeding a defined number of drugs \[[@CR10]\]. Intervention: a paper must have explored the effect of a deprescribing intervention which included any medication review that was in line with the definition agreed by the Pharmaceutical Care Network Europe 2013. \[[@CR28]\]. Comparator: a study must have included a control to have been eligible for inclusion. Outcomes: a paper must have reported data on adherence, measured by any means; i.e., pill count, self-reported, questionnaire, 'drug or prescription or medications' 'renewal or refill', blood level analysis. Adherence could have been reported as a primary or a secondary outcome. Any study that did not report adherence was excluded.

Search strategy {#Sec4}
---------------

An information scientist (DH) undertook a comprehensive search of eight bibliographic databases between May and August 2017: ASSIA (ProQuest), CENTRAL (Wiley), CINAHL (EBSCO), MEDLINE (EBSCO), PsycINFO (ProQuest), Scopus (Elsevier), Sociological Abstracts (ProQuest), Web of Science (Thomson Reuters). Two clinical trials registers were searched in December 2017: UK Clinical Trials Gateway (NHS, National Institute for Health Research), International Clinical Trials Registry Platform (World Health Organization).

The search strategy comprised four facets: (i) older people, and (ii) polypharmacy, deprescribing or medications reviews, and (iii) adherence or instruments/measurements relating to adherence, and (iv) the community setting, such as independent living, or the community based professional delivering the intervention. All terms were searched for in the title and abstract fields and controlled vocabulary terms were included where available. The Boolean operators AND and OR were used, alongside truncation, phrase searching and proximity operators. Only papers published in the English language were sought, no date limits were applied. The search syntax was adapted for use on each information source. The full search strategy, written up for MEDLINE (EBSCO) is provided in Additional file [1](#MOESM1){ref-type="media"}: Appendix 1.

Data management {#Sec5}
---------------

The bibliographic software, RefWorks (ProQuest) was used to store and organise all results from the bibliographic databases, and Excel was used for results from the clinical trials registers. Microsoft Excel 2015 was used to support the selection of papers and data extraction process, and Microsoft Word 2015, the quality appraisal process.

Study selection {#Sec6}
---------------

All papers retrieved from the literature searches were assessed against the inclusion criteria. The study selection process was piloted by all members of the review team using a sample of 100 papers. All results were independently screened by two members of the review team. In the first instance the title and abstract of all papers were screened to determine their relevancy, followed by a full text screening of all remaining papers. Any disagreement in screening outcome between reviewers was resolved through discussion or the use of a third reviewer. Reviewers were not blinded to a paper's author/s.

Data extraction {#Sec7}
---------------

An a priori data collection instrument was created and piloted by the review team. Data extraction was undertaken by one reviewer and double checked for accuracy by a second. Any discrepancies were resolved through discussion and further scrutiny of the included paper. Extracted data were as follows: information on the author/s, year of publication, name of paper, title of journal; the study setting, duration and geographic location; the study type, design, aim, objectives, context, and data collection and analysis techniques; the number of participants, participant demographics, e.g. age, gender, baseline cognitive function, number of medications taken, health conditions experienced; the aim and description of the intervention, the intervention instrument, baseline adherence, how the intervention was delivered; time from the intervention to the follow-up; theoretical framework underpinning an intervention; author stated strengths/weaknesses and conclusions; reviewers comments. Outcomes of adherence included: (i) the adherence measure reported, (ii) the number of drugs prescribed and their appropriateness, (iii) and whether the adherence measure improved with intervention or not. Secondary measures of interest included: self-reported quality of life, primary care visits, hospital visits and mortality; indicators of acceptability to users, and evidence of shared decision making.

Risk of bias in individual studies {#Sec8}
----------------------------------

The Mixed Methods Quality Appraisal Tool (MMAT) \[[@CR29]\] was used to explore the risk of bias at study level. An overall quality score was attributed to each study. An incremental score of 25% is given for each of the four criteria met for quantitative and qualitative studies and each of the three criteria for mixed methods studies.

Data synthesis {#Sec9}
--------------

Qualitative and quantitative data were analysed separately. If a paper reported mixed methods data, a decision was taken as to what the majority of the data comprised. The quantitative data was not homogenous; there was variability in data collection, data source, and statistical analysis across most studies. Therefore for the quantitative studies, a narrative synthesis approach was taken. The qualitative data was analysed using Framework Analysis \[[@CR30]\]. Findings were integrated using the 'Following a Thread' technique described by O'Cathain et al., \[[@CR31]\]. Using this approach all data sets were scanned for key themes and questions in need of further exploration.

Results {#Sec10}
=======

A total of 1980 unique papers were yielded from the database searches, and an additional 140 papers from the clinical trials registers searches. Screening title and abstracts resulted in 119 papers being retained from the database searches and 21 papers from the clinical trials registries. After full-text reading, author citation and reference list evaluation a total of 22 met the eligibility criteria and underwent quality appraisal and data extraction processes. Nine additional trials were found, but no data was found due to either non-publication or ongoing research. The literature review screening process is summarised in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1PRISMA flow diagram

Outcomes from the MMAT exercise for the 22 papers from the database searches showed that ten studies scored 100%, six scored 75% and six scored 50% or less. Non-RCT data exhibited somewhat greater risk of bias (see MMAT summary Table [1](#Tab1){ref-type="table"}). Quantitative and qualitative findings were collated but the framework analysis was limited by the very small amount of qualitative data about adherence, medicines' management methods and patient outcomes. A summary of study characteristics are presented in Table [2](#Tab2){ref-type="table"}.Table 1Summary of MMATCriteria2.1 Randomisation2.2 Concealment /blinding2.3 Complete outcomes2.4 Loss to follow up3.1 Recruitment3.2 appropriate measures3.3 Comparable groups3.4 Complete outcomes4.1 Relevant sampling4.2 Representative sampling4.3 Appropriate measures4.4 Response rateOverall scoreStudyRCTs Basheti 2016 \[[@CR34]\]√√√√100% Beer 2011 \[[@CR52]\]√X√X50% Campins 2017 \[[@CR32]\]√√√√100% Grymonpre 2001 \[[@CR45]\]√√X√75% Haag 2016 \[[@CR33]\]√√√√100% Lowe 2000 \[[@CR47]\]√√√√100% Hanlon 1996 \[[@CR48]\]√√√√100% Hedegaard 2015 \[[@CR36]\]√√√X75% Jager 2017 \[[@CR50]\]√√√X75% Sturgess 2003 \[[@CR44]\]√XXX25% Vinks 2009 \[[@CR43]\]√√√√100% Messerli 2016 \[[@CR53]\]√√√√100%Average83.3%Non-RCTs Chen 2016 \[[@CR35]\]√√X√75% Fiss 2013√XX√50% Griffiths 2004 \[[@CR51]\]√√XX50% Lee 2015 \[[@CR38]\]√√√√100% Steele 2016 \[[@CR37]\]X√√√75% Hatah 2014 \[[@CR41]\]XXX√25% Tan 2014 \[[@CR40]\]X√XX25% Twigg 2015 \[[@CR39]\]√√√√100% Raynor 2000 \[[@CR46]\]√√X√75% Roth 2013 \[[@CR42]\]√√√√100% Average67.5%Table 2Summary of study characteristicsRefStudy designSettingStudy duration (months)Total number of participants (*N* = intervention group where relevant)Type of intervention/ person leadingUsual care (if applicable)Adherence outcomeBasheti 2016\
JordanRCTOutpatient Clinic3112\
(*N* = 50)Follow up Pharmacist led medication reviewRoutine clinical practiceReduction in self- reported non-adherence in intervention group (*P* \< 0.001) compared with control group (*P* = 0.168)Beer 2011\
AustraliaRCTHome setting and residential aged-care facilityUnknown30\
(*N* = 15)Physician led targeted medication withdrawalUsual careNo significant difference between the groups\
*P* = 0.17Campins 2017\
SpainRCTPrimary care centres12503\
(*N* = 252)Pharmacist led medication reviewRoutine clinical practiceAt 6 months adherence was higher in the intervention group (76.4% v 64.1%) *P* = 0.005Grymonpre\
2001 CanadaRCTCommunity based clinicVariable\
(from baseline to follow up letter)135\
(*N* = 69)Pharmacist led medication reviewRoutine clinical practiceNo significant impact on adherence from baseline to follow-up (*P* = 0.895)Haag 2016\
USARCTPrimary care outpatient clinic125\
(*N* = 13)Pharmacist led medication reviewPre-existing out-patient care transition programmeNo significant difference in adherence *P* = 0.65Hanlon 1996\
USARCTGeneral Medicine Clinic at Veterans Affairs Medical Centre12208\
(*N* = 105)Pharmacist led medication reviewUsual careNo significant difference in medication compliance (*P* = 0.88)Hedegaard 2015\
DenmarkRCTOutpatient clinics12532\
(*N* = 240)Pharmacist led medication reviewRoutine clinical practiceTrend toward improved adherence at 3, 9 and 12 months. Greater % of control group non-adherent compared with intervention group 30.2% vs 20.3% *P* = 0.01.Jaeger 2017\
GermanyRCTGP Practices9273\
(*N* = 143)Tailored medication review programme delivered by GPs and Health Care AssistantsRoutine clinical practiceNo significant effects on adherence *P* = 0.11Lowe 2000\
UKRCTGeneral Practice / Home setting3161\
(*N* = 77)Pharmacist led reviewRoutine clinical practiceSignificant difference in mean compliance score (tablet count and self --reported). Intervention group = 91.3% vs 79.5% control group. *P* \< 0.001Sturgess 2003\
Northern IrelandRCTCommunity Pharmacies18191\
(*N* = 110)Community Pharmacist intervention programmeRoutine PracticeSignificant increase in compliance and fewer problems with medication compared with control group (*P* \< 0.05)Vinks 2009\
NetherlandsRCTCommunity Pharmacy4174\
(*N* = 87)Community Pharmacist reviewUsual PracticeSignificant reduction in the number of drug related problems per patient (includes non-compliance) -16.3% (−24.3,-8.3) 95% CIMesserli 2016\
SwitzerlandRCTCommunity Pharmacy7450\
(*N* = 218)Community Pharmacist\
Polymedication Check (PMC)Routine practiceNo significant difference in adherence between the two groups could be observed (*p* = 0.817)Chen 2016\
TaiwanProspective cross-sectionalOutpatient clinics3152Pharmacist led medication therapy management serviceIncrease in medication adherence (MMAS-4 scale) from 3.02 to 3.92 (*p* \< 0.001)Fiss 2013\
GermanyProspective cohortAmbulatory primary healthcare1--24\
(mean = 9)911\
(*N* = 393)Pharmaceutical care from local pharmacy plus medical intervention by GPIncreased in adherence forgetfulness *P* = 0.001\
Increased adherence deliberate *p* = 0.003\
(*n* = 400) between baseline and follow upGriffiths 2004\
AustraliaCohortCommunity / Home setting1*N* = 24Community nurse medication reviewRoutine clinical practiceNo significant difference in non-adherence pre and post intervention\
(*P* = 0.237)Hatah 2014\
New ZealandRetrospective cohortCommunity Pharmacy6 to 41*N* = 353Community Pharmacist Medicines Use Review (MUR)No significant difference except during the third visit where more patients with lower adherence scores did not return *P* \< 0.001Lee 2015\
Hong KongProspective UncontrolledCommunity outreach8*N* = 103Pharmacist led reviewRoutine clinical practiceSignificant reduction in Morisky Medication Adherence score *P* = 0.005Raynor 2000\
UKCohortCommunity Pharmacy/home setting2*N* = 143Community Pharmacist led medication adherence supportRoutine practiceNon-adherence fell from 38% to 14% (*P* \< 0.001)Roth 2013\
USAProspectiveCommunity based primary care medical practice664Clinical Pharmacist led medication reviewRoutine clinical practiceSignificant reduction in the number of medication related problems per patient (*P* \< 0.001)\
which included non- adherenceSteele 2016\
USAProspective StudyHome based325Pharmacist conducted home based medication reviewRoutine practiceNon- adherence was significantly reduced (*P* = 0.012)Tan 2014\
AustraliaProspective StudyCommunity clinic/ home setting682Pharmacist led reviewRoutine practiceSignificant improvement in adherence (44.1% v 62.7% *P* = 0.023)Twigg 2015\
UKService EvaluationCommunity Pharmacy6620Community Pharmacist ReviewRoutine PracticeSignificant increase in adherence 0.513 .337 to 0.689) 95% CI

Studies and participants {#Sec11}
------------------------

Twenty-two studies in 13 different countries were included (10 in Europe, 5 in North America, 7 elsewhere (Australia, New Zealand, Taiwan, Hong Kong and Jordan), with publication dates between 1996 and 2017, involving 5118 participants. Thirteen studies were controlled clinical trials (1 non-randomised), and nine were cross-sectional studies. The age range of the participants was 46 and 97 years. Three studies included patients \< 65 years, 13 studies age range 65--85, 6 studies included patients \>86y. Eight study interventions were based in primary care or GP practices, seven in community pharmacies, three in an outpatient clinic, two as home visits, one as remote prescribing and one from a community centre for older people. The follow-up period for the interventions ranged between four weeks and 41 months, with a mean of eight months.

Types of interventions {#Sec12}
----------------------

The healthcare professional leading the intervention varied significantly. Most commonly, a pharmacist led (in 18 studies \[[@CR32]--[@CR48]\], while a GP and pharmacist co-led in 1 study \[[@CR49]\], a GP alone in another study \[[@CR50]\], a community nurse led in another study \[[@CR51]\] and the participants themselves led in another \[[@CR52]\]. While all interventions included a process of deprescribing, study interventions used 'deprescribing' specifically in nine studies \[[@CR32], [@CR35], [@CR40], [@CR42], [@CR47], [@CR48], [@CR52], [@CR53]\], while in 12 studies the description was 'medication use review' \[[@CR33], [@CR34], [@CR36]--[@CR38], [@CR41], [@CR43]--[@CR46], [@CR49]--[@CR51]\].

Where specific deprescribing tools were used they included the GP-GP (good palliative-geriatric practice) \[[@CR32]\], STOPP/START, 2 \[[@CR32], [@CR39]\], Beers, 1 \[[@CR52]\], e-medicines information, one \[[@CR35]\], IMAP (individualised medication assessment and planning program), 1 \[[@CR42]\]. In four studies no particular deprescribing tool was mentioned \[[@CR40], [@CR47], [@CR48], [@CR52]\]. Only four of the 22 studies yielded significant reductions in tablet burden \[[@CR32], [@CR46], [@CR47], [@CR50]\]. Regime complexity, i.e. the frequency and dosing, was not recorded in any of the studies. Of those studies with no decrease in overall medications; seven demonstrated a comparable number pre- and post-intervention \[[@CR33], [@CR36], [@CR42], [@CR43], [@CR45], [@CR48], [@CR52]\]; 1 study reported an overall increase \[[@CR44]\], and nine did not record the numbers (either pre or post) \[[@CR34], [@CR35], [@CR37]--[@CR41], [@CR49], [@CR51], [@CR53]\].

Medication adherence {#Sec13}
--------------------

Thirteen studies reported improved adherence following study interventions \[[@CR32], [@CR34]--[@CR41], [@CR43], [@CR46], [@CR47], [@CR50]\] of which 5 studies were RCTs. Of the four studies that report a reduction in medication burden, all reported improved adherence \[[@CR32], [@CR46], [@CR47], [@CR50]\]. Exclusion of studies at moderate to high risk of bias (MMAT score 50% or less) did not alter the overall findings. The adherence tool varied between studies, but not to the same extent as the intervention tool. The Morisky-Green scale or a derivative was used in 10 studies \[[@CR32]--[@CR35], [@CR38]--[@CR40], [@CR42], [@CR46], [@CR49], [@CR52]\]; Medication possession ratio/pill count in five studies \[[@CR36], [@CR37], [@CR43], [@CR45], [@CR49], [@CR52]\]; self-report only in three studies \[[@CR48], [@CR50], [@CR51]\] and self-report and pill count in three studies \[[@CR44], [@CR47], [@CR50]\]. An unspecified adherence scale was used in one study \[[@CR41]\]. All studies reported adherence as a secondary outcome, except Twigg \[[@CR39]\] and Messerli \[[@CR53]\]. The proposed mechanisms of success for those that reported improved adherence were: reduced number of medications, 1 \[[@CR32]\]; good relationship between clinical professionals/ collaborative working, 3 \[[@CR34], [@CR43], [@CR50]\]; practical aspect only, 1 \[[@CR45]\]; educational or motivational impact, 5 \[[@CR36], [@CR38]--[@CR41]\], both practical and behavioural impact, 3 \[[@CR35], [@CR37], [@CR47]\].

In terms of the secondary measures of interest, self-reported quality of life was reported in five of the 22 studies \[[@CR32], [@CR34], [@CR39], [@CR44], [@CR48]\], of which one study \[[@CR39]\] reported an improvement. The other four studies had no statistical impact. Primary care visits were reported in four studies \[[@CR32], [@CR39], [@CR40], [@CR44]\] of which one study reported a change in number of visits \[[@CR39]\] (an increase from a mean of 1.65 to 2.04 visits per patient in a 6 month period). Unplanned or emergency care visits were reported in 6 studies \[[@CR32], [@CR33], [@CR39], [@CR40], [@CR42], [@CR44]\]. Two studies suggested that interventions resulted in reductions to unplanned care but this was not statistically significant; four studies demonstrated no impact on unplanned or emergency care. Mortality was reported in four studies \[[@CR32], [@CR33], [@CR44], [@CR45]\]; none of these reported any impact.

Discussion {#Sec14}
==========

The issue of adherence is manifestly complicated. A broad range of studies was deliberately included to enhance understanding of the potential mechanisms of any intervention effect but qualitative data were limited. It is clear that no routine or consistent method of deprescribing is implemented, and no consistent outcome from the practice, such as a reduction in the number of prescriptions, is reported. Therefore it was impossible to demonstrate that an improved adherence was a consequence of a reduced medication burden.

Adherence is regarded as an important indicator of the quality of the doctor--patient relationship \[[@CR54]\] and by extension that offered by other multidisciplinary team members. It is important to note that there are different understandings of adherence according to clinical and research priorities. This study identified that improved adherence depended on the measurement tool and the method of statistical analysis. For example, a self-report scale questionnaire would differ in analysis to the proportion of days covered. One study incorporated the understanding of the individual as to the purpose of each of their medications \[[@CR41]\], where others merely counted the number of pills left at the end of a month \[[@CR36], [@CR37], [@CR43], [@CR47]\].

There is an extremely mixed body of literature reporting strategies to improve medication adherence \[[@CR55]\]. Adherence was measured as a secondary outcome in all but two studies which meant that more subtle reasons for non-adherence could not be established from this review. Follow-up periods were generally short, making it difficult to draw any conclusions as to the lasting impact of the interventions themselves.

The range of professional practitioners engaged in deprescribing implies that international models of practice are continuing to adopt an interdisciplinary team approach. Of the three studies that did not involve pharmacists, none showed a difference in adherence measures. Of the 18 remaining studies, the majority (13 studies) demonstrated improved outcomes. From this review it would seem that pharmacist-led deprescribing interventions are effective.

Independent prescribing status in the UK has been awarded by the General Pharmaceutical Council since 2006 and nurses, podiatrists, physiotherapists and therapeutic radiographers may complete additional post-registration training to become independent prescribers \[[@CR56]\]. One study commented that the success of the intervention depended, in large part, on the physician's acceptance of the recommended changes in a person's medications \[[@CR34]\]. Collaborative working between professionals to achieve deprescribing or increased adherence may be key to the success of these interventions.

A systematic method of enhancing the quality of research into medication use is now being proposed, particularly focusing on seven factors that are consistent with the findings of this study; vulnerable patient populations; polypharmacy and multi-morbidity; person-centered practice and research; deprescribing or medicines use review; methodological development; variability in medication use; and national and international comparative research \[[@CR56]\].

From this review there is little data suggesting that deprescribing interventions improve outcomes such as quality of life, primary or secondary care visits or affect mortality \[[@CR57]\]. On the other hand, neither is there much evidence that these interventions lead to a negative impact on these measures; something that has already been suggested elsewhere \[[@CR58]\]. Large RCTs evaluating multidisciplinary interventions and clinical outcomes of deprescribing are lacking \[[@CR59]--[@CR61]\], but there are examples of individual studies suggesting that deprescribing can improve outcomes such as falls, hospital admissions and mortality \[[@CR62]\].

There was a surprisingly low level of reporting of socio-economic components. In a sub group analysis of four studies that reported both deprescribing with reduction in medication and an improvement in adherence the intervention cohort (*N* = 847) were 44% men and 56% women. The studies reported inconsistently, on marital status educational level and household income. Further consideration of these socio-economic components is indicated to deliver a patient-centred deprescribing process \[[@CR63], [@CR64]\].

The strengths of this review include careful attention to screening and data extraction of the adherence outcome and the focus on the outcome of the complex medicines management intervention. 'Deprescribing' was carefully defined to include all forms of medication review interventions where the intention was to reduce treatment burden.

The evidence found was from different study designs: RCTs, prospective/ retrospective cohort, prospective cross-sectional, cohort and prospective uncontrolled and is a limitation of the literature. Meta-analyses of data were not possible, and this is a limitation, owing to the diversity of measures used in calculating adherence. A number of potentially interesting sub-group analyses (e.g. ethnicity, degree of frailty, economic impact of intervention) could not be completed due to varied and incomplete reporting of populations studied, interventions delivered, and outcome measurements. Qualitative data analysis revealed a number of factors associated with non-adherence but limited narrative explanation was possible within the data.

Conclusion {#Sec15}
==========

This systematic review found that deprescribing as an intervention did not routinely improve medication adherence in this patient population. The theory that a reduced medication burden would improve adherence could not be substantiated in the literature. This is because the interventions described in the studies did not convincingly reduce medication burden. There is a range of bio-psycho-social factors reported that associate with improved adherence, but medicines review processes vary and rarely report the population demographic. Adherence is mostly reported as a secondary outcome and there is no standard report of successful adherence to medication. The authors recommend further study into the efficacy and outcomes of medicines management interventions. A consensus on priority outcome measurements for prescribed medications is indicated.
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ASSIA

:   Applied Social Sciences Index and abstracts

CENTRAL

:   Cochrane Central Register of Controlled Trails

CINAHL

:   Cumulative Index to Nursing and Allied Health Literature

MEDLINE

:   Medical Literature

MMAT

:   Mixed Methods Quality Appraisal Tool

PRISMA

:   Preferred Reporting Items for Systematic review and Meta-Analysis

PROSPERO

:   Prospective Register of Systematic Reviews

PsycINFO

:   Psychology Informatics

RCT

:   Randomised Controlled Trial

USA

:   United States of America
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